Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab versus ustekinumab in pediatric moderate to severe plaque psoriasis
2023-503859-10-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Bimekizumab arm with Ustekinumab arm (2 arms). Primary endpoints: PASI90 response at Week 16 and IGA 0/1 response at Week 16. Planned start Jul 2024; status: authorised.
02
Drugs
bimekizumabustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-503859-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503859-10-00.